RESTASIS^® & Other Treatments

Your patients with Chronic Dry Eye may already have used or are currently using other treatment options. This section is designed to discuss, in the context of what other treatments can do, what RESTASIS^® Ophthalmic Emulsion can do for patients with a certain type of Chronic Dry Eye.

In this section:

• How Does RESTASIS^® Differ From Artificial Tears?
• Concomitant Use Of RESTASIS^® With Artificial Tears
• RESTASIS^® and Punctal Plugs

© 2007 Allergan, Inc. All rights reserved | Privacy Statement | FAQs | Terms of Use | Site Map
This information is intended for residents of the United States. ® and ™ marks owned by Allergan, Inc.

RESTASIS^® Ophthalmic Emulsion is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.

Important Safety Information:

RESTASIS^® is contraindicated in patients with active ocular infections and has not been studied in patients with a history of herpes keratitis.

The most common adverse event was ocular burning (upon instillation) – 17%. Other events reported in 1% to 5% of patients included conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, and visual disturbance (most often blurring).

Please see full prescribing information for RESTASIS^® (cyclosporine ophthalmic emulsion) 0.05%.